Wall Street analysts predict that Mersana Therapeutics Inc (NASDAQ:MRSN) will post earnings of ($0.37) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Mersana Therapeutics’ earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.35). Mersana Therapeutics posted earnings of ($0.75) per share during the same quarter last year, which suggests a positive year over year growth rate of 50.7%. The business is expected to report its next quarterly earnings results on Tuesday, November 12th.
According to Zacks, analysts expect that Mersana Therapeutics will report full year earnings of ($0.64) per share for the current financial year, with EPS estimates ranging from ($0.86) to ($0.38). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.84) to ($1.20). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $1.08 million. Mersana Therapeutics had a negative return on equity of 63.92% and a negative net margin of 77.78%.
Shares of NASDAQ:MRSN traded down $0.02 during midday trading on Friday, reaching $2.82. 552 shares of the company’s stock were exchanged, compared to its average volume of 151,308. The stock has a 50 day moving average price of $3.80. The company has a current ratio of 6.24, a quick ratio of 6.24 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $148.69 million, a PE ratio of -1.00 and a beta of 1.37. Mersana Therapeutics has a fifty-two week low of $2.79 and a fifty-two week high of $15.93.
A number of hedge funds have recently bought and sold shares of MRSN. Northern Trust Corp grew its stake in shares of Mersana Therapeutics by 13.4% in the second quarter. Northern Trust Corp now owns 204,194 shares of the company’s stock valued at $827,000 after buying an additional 24,126 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in shares of Mersana Therapeutics during the 2nd quarter worth $94,000. Renaissance Technologies LLC boosted its stake in shares of Mersana Therapeutics by 52.4% during the 2nd quarter. Renaissance Technologies LLC now owns 266,020 shares of the company’s stock worth $1,077,000 after acquiring an additional 91,500 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Mersana Therapeutics by 176.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 107,201 shares of the company’s stock worth $434,000 after acquiring an additional 68,457 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Mersana Therapeutics by 144.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 85,045 shares of the company’s stock worth $345,000 after acquiring an additional 50,195 shares in the last quarter. Hedge funds and other institutional investors own 77.40% of the company’s stock.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Featured Story: What is Put Option Volume?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.